Membranous nephropathy posttransplantation: an update of the pathophysiology and management

Leon, Juliette; Pérez-Sáez, María José; Batal, Ibrahim; Beck, Laurence H. Jr; Rennke, Helmut G.; Canaud, Guillaume; Legendre, Christophe; Pascual Santos, Julio; Riella, Leonardo V.

doi:http://dx.doi.org/10.1097/TP.0000000000002758

Membranous nephropathy posttransplantation: an update of the pathophysiology and management

Citation

Leon J, Pérez-Sáez MJ, Batal I, Beck LH Jr, Rennke HG, Canaud G, et al. Membranous nephropathy posttransplantation: an update of the pathophysiology and management. Transplantation. 2019 Oct; 103(10):1990-2002. DOI: 10.1097/TP.0000000000002758

Abstract

Membranous nephropathy (MN) is a common cause of nephrotic syndrome after transplantation and is associated with an increased risk of allograft loss. MN may occur either as a recurrent or as a de novo disease. As in native kidneys, the pathophysiology of the MN recurrence is in most cases associated with antiphospholipid A2 receptor antibodies. However, the posttransplant course has some distinct features when compared with primary MN, including a lower chance of spontaneous remission and a greater requirement for adjuvant immunosuppressive therapy to induce complete remission. Although the efficacy of rituximab in primary MN is now well established, no randomized studies have assessed its effectiveness in MN after transplant, and there are no specific recommendations for the management of these patients. This review aims to synthesize and update the pathophysiology of posttransplant MN, as well as to address unsolved issues specific to transplantation, including the prognostic value of antiphospholipid A2 receptor, the risk of living-related donation, the link between de novo MN and rejection, and different therapeutic strategies so far deployed in posttransplant MN. Lastly, we propose a management algorithm for patients with MN who are planning to receive a kidney transplant, including pretransplant considerations, posttransplant monitoring, and the clinical approach after the diagnosis of recurrence.